<DOC>
	<DOCNO>NCT02109692</DOCNO>
	<brief_summary>Duchenne muscular dystrophy ( DMD ) , cause mutation DMD gene , common severe progressive dystrophy child . Although development rapidly progressive , variability severity disease DMD patient correlate type mutation DMD gene . There easily measurable biomarkers monitor DMD moderate form disease , Becker muscular dystrophy ( BMD ) . MicroRNAs ( miRNAs ) involve cellular process , expression pattern signature state cell . They represent potential class diagnostic prognostic biomarkers . Some specific skeletal myogenesis , change pattern expression associate muscle disease include muscular dystrophy . The level muscle- specific miRNAs indeed greatly increased serum DMD BMD compare control patient . The main objective validate use serum muscle-derived microRNAs biomarkers DMD patient ( compare healthy subject ) . Secondary objective ) investigate relationship circulating level miRNAs severity dystrophinopathy ( DMD v BMD ) also progression disease ( longitudinal study ) , ii ) ass specificity marker dystrophinopathy ( comparison patient muscular dystrophy ) , iii ) test candidate miRNAs recently identify yet analyze serum patient . Clinical data sample record regular consultation . miRNA level quantify use Real Time Quantitative RT-PCR .</brief_summary>
	<brief_title>Evaluation Muscle miRNA Biomarkers Dystrophinopathies</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<criteria>Patient suffers dystrophinopathy muscle dystrophy , Healthy volunteer sign informed consent social insurance patient parent sign informed consent ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>dystrophinopathies</keyword>
	<keyword>muscle dystrophy</keyword>
	<keyword>dystromirs</keyword>
	<keyword>longitudinal study</keyword>
	<keyword>miRNA</keyword>
</DOC>